Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Receivables (2016 - 2025)

Macrogenics (MGNX) has disclosed Receivables for 14 consecutive years, with $13.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 210.35% to $13.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.4 million, a 210.35% increase, with the full-year FY2025 number at $13.4 million, up 210.35% from a year prior.
  • Receivables was $13.4 million for Q4 2025 at Macrogenics, down from $69.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $69.2 million in Q3 2025 to a low of $4.3 million in Q4 2024.
  • A 5-year average of $19.5 million and a median of $13.0 million in 2025 define the central range for Receivables.
  • Peak YoY movement for Receivables: tumbled 81.56% in 2023, then skyrocketed 691.2% in 2025.
  • Macrogenics' Receivables stood at $10.4 million in 2021, then skyrocketed by 441.32% to $56.2 million in 2022, then crashed by 81.56% to $10.4 million in 2023, then plummeted by 58.44% to $4.3 million in 2024, then surged by 210.35% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Receivables are $13.4 million (Q4 2025), $69.2 million (Q3 2025), and $12.5 million (Q2 2025).